On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...

Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $160.7 billion, announced Thursday that its Phase 3 VESALIUS-CV clinical ...

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that regulates LDL cholesterol levels in the bloodstream. The medication is approved in more than 74 countries for reducing ...

SANTA MONICA, Calif., October 06, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a ...

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...